Hundreds of millions of people are taking or will soon take GLP-1 medications for the treatment of obesity and diabetes, Aparna Kamat, MD, director of the Division of Gynecologic Oncology at Houston Methodist Hospital, told Medical News Today
The aim of the present narrative review was to describe the gastrointestinal adverse effects of the antidiabetic drugs, their pathophysiologic mechanisms, and the corresponding therapeutic measures
As of June 2025, the branded version of liraglutide, Saxenda, generated $165 million in annual sales alone, and the market for GLP-1s could be set to hit over $126 billion in sales by 2029
AK, ST and S are grateful to CSIR for SRF and RA, respectively
Compared to non-GLP-1RA anti-diabetes medications, semaglutide was associated with a significantly lower risk of incident AUD diagnosis (0.32% vs 0.52%
While the various studies tried to account for those differences, none can prove the drugs improve cancer outcomes